When clonidine (Catapres) and methyldopa (Aldomet, Dopamet, Medomet) were first introduced, they had advantages over other antihypertensive drugs then available. Now, however, their unwanted effects compare less favourably with those of newer antihypertensive regimens. Are they still needed at all?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.